Q-omics provides the consensus-scored C9orf129 profile across patient tissues and cancer cell-line models. C9orf129 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, C9orf129 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, C9orf129 RNA expression shows 13,482 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UCS, THCA, and PCPG as cancer lineages where C9orf129 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf129 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf129 survival associations across molecular data types. C9orf129 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf129 RNA expression–survival associations across cancer types. High C9orf129 expression shows unfavorable associations in UCS, DLBC, THCA and ACC, but favorable associations in OV and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for C9orf129 RNA expression.
This table summarizes C9orf129 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C9orf129. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf129 shows lower tumor expression in THCA, LUAD, ESCA and PRAD and higher tumor expression in HNSC and KIRC. The THCA box plot shows higher C9orf129 RNA expression in normal versus tumor tissue (log2 FC = −0.057, t-test p = .001).
This table shows molecular features associated with C9orf129 in patient tissues and cancer cell lines. In patient samples, C9orf129 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf129 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
